Market Signal Briefing

NEW YORK, March 08, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alight, Inc. (NYSE: ALIT) resulting from allegations that Alight may have issued materially misleading business information to the investing public.

So What: If you purchased Alight securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=54542 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On February 19, 2026, before the market opened, Alight issued a press release entitled “Alight Reports Fourth Quarter and Full Year 2025 Results”. Among other metrics, the release stated disclosed results of “[g]ross profit of $240 million and gross profit margin of 36.8%, compared to $271 million and 39.9% in the prior year period, respectively, and adjusted gross profit of $272 million and adjusted gross profit margin of 41.7%, compared to $300 million and 44.1% in the prior year period, respectively[.]”

On this news, Alight stock fell 38.2% on February 19, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

I recommend selling Breakwave Tanker Shipping ETF due to an unattractive risk-return profile after its dramatic 2026 surge. BWET's performance is tightly linked to the Middle East maritime oil freight, especially the Strait of Hormuz, making it highly sensitive to geopolitical disruptions. Oil shipping prices and BWET have already soared to levels not seen since the 2000s; further upside appears limited as conflict escalation is not in major powers' interests.

📊
No votes yet – Be the first to vote

XRP crashed hard again. The token’s wild price swings left investors holding bags worth way less than what they paid, and Glassnode’s latest data shows the brutal reality facing millions of holders right now.

Most XRP buyers are pretty much underwater at current prices. They bought tokens when XRP was flying high, but now they’re stuck watching their investments bleed red every day. The numbers don’t lie – $50.8 billion in unrealized losses sits on the books, and that’s just what we can track. Many holders bought near XRP’s $1.96 peak back in early 2021, and today’s price action makes those purchases look really painful. Traders who jumped in during the hype cycles are now facing some tough choices about whether to cut losses or keep holding through this mess.

Not exactly shocking news.

The crypto market’s brutal nature isn’t new, but XRP’s journey shows just how fast things can flip. One day you’re celebrating massive gains, the next you’re calculating how much you’ve lost and wondering if you’ll ever break even again. And XRP holders know this feeling all too well – they’ve been through multiple cycles of hope and disappointment over the past few years.

Current market pressure keeps building on XRP investors. They’re stuck between selling at huge losses or holding on and praying for some kind of miracle recovery that might never come.

But XRP’s problems go way deeper than just market volatility. Ripple Labs, the company behind XRP, can’t shake the SEC lawsuit that’s been dragging on since December 2020. Legal uncertainty kills investor confidence faster than almost anything else in crypto, and this case has been hanging over XRP like a dark cloud for years now. Every time it looks like there might be some resolution, the case drags on longer and sentiment gets worse.

Brad Garlinghouse keeps talking tough about winning the lawsuit. “We’re confident in our position,” he said during a recent interview, but confidence doesn’t pay the bills for underwater investors. The CEO’s optimism hasn’t translated into price gains, and many holders are getting tired of waiting for legal clarity that seems to never arrive. For more details, see XRP Could Hit ,000 This Year.

Regulatory mess continues plaguing XRP.

Market dynamics for the token remain pretty murky. Institutional investors who might normally step in during these kinds of dips are staying away because of the legal risks. Grayscale and other big players have been exploring crypto opportunities, but XRP’s regulatory baggage makes it a harder sell than cleaner tokens like Bitcoin or Ethereum. Without institutional buying pressure, retail investors are basically on their own trying to prop up the price.

Trading volumes tell the real story about investor sentiment. Data from major exchanges shows people are making smaller, more cautious trades instead of big confident bets. Nobody wants to catch a falling knife, especially when that knife might get hit with more regulatory problems down the road. Volume patterns suggest most traders are sitting on the sidelines waiting for clearer signals.

Ripple tried throwing some good news into the mix recently. The company announced a partnership with a major financial institution in February 2026, hoping to show that XRP still has real-world utility despite all the legal drama. Partnerships sound great in press releases, but they haven’t moved the needle much on price action so far.

The XRP community keeps grinding through all this uncertainty. Some holders express frustration with how long everything’s taking, while others maintain faith that a favorable SEC ruling could trigger a massive price surge. Community sentiment stays mixed – nobody really knows what’s coming next, and that uncertainty keeps weighing on the token’s performance. This follows earlier reporting on Bitcoin Holders Who Wait Three Years.

Current price levels make the loss calculations pretty stark. Anyone who bought XRP above today’s trading range is sitting on red numbers, and the gap between purchase prices and market value keeps growing. March 2026 data from Glassnode shows most trading activity happening at these lower price levels, which means new buyers aren’t exactly rushing in to support higher valuations.

Ripple Labs hasn’t offered much guidance to worried investors lately. The company stays focused on fighting the SEC case and building business partnerships, but holders want to see concrete progress that actually moves the price upward. Until something major changes – either legal resolution or massive adoption news – XRP investors will probably keep staring at those unrealized loss numbers and wondering when their patience might finally pay off.

The SEC lawsuit’s financial impact extends beyond just legal fees for Ripple Labs. Court documents reveal the company has spent over $200 million defending against the charges, money that could have gone toward technology development or market-making activities. Former SEC officials like John Reed Stark have pointed out that prolonged cases often drain resources from both sides, creating a lose-lose scenario that benefits nobody. Meanwhile, other crypto projects have used this regulatory uncertainty to position themselves as “cleaner” alternatives to XRP in the payments space.

International markets tell a different story about XRP adoption. Japan’s financial regulators approved XRP for trading years ago, and the token maintains strong liquidity on exchanges like Bitbank and Coincheck. European crypto platforms including Bitstamp and Kraken continue listing XRP despite U.S. regulatory concerns. This geographic split creates an odd situation where American investors face restrictions while overseas traders can buy and sell freely, potentially limiting XRP’s growth in one of crypto’s biggest markets.

Post Views: 16

Bitcoin fell nearly 2% in just 15 minutes on Sunday while oil prices rose almost 20% as the escalating Middle East conflict prompted fears of a major supply shortage in the global energy market.

Data from decentralized derivatives platform Hyperliquid shows oil prices rose from $95 to $113.7 per barrel shortly after US futures markets opened, as Iraq warned that roughly 3 million barrels per day of production could be disrupted due to Iranian threats against tankers in the Strait of Hormuz.

It’s the highest price oil has reached since April 2022, a few weeks after Russia commenced its invasion of Ukraine, TradingView data shows. 

The price of oil rose more than 30% last week after the US and Israel struck Iran, leading the war-torn nation to counterstrike against several of its Middle Eastern neighbors.

Bitcoin (BTC) fell from $66,960 to $65,725 by 10:30 pm UTC on Sunday as US futures markets opened before bouncing back up to $66,272 at the time of publication.

Hyperliquid data also shows that oil prices have cooled off to $105 per barrel.

Change in oil price since Wednesday. Source: HyperliquidBitcoin climbed during the Middle Eastern conflict last week, which saw the death of Iranian Supreme Leader Ayatollah Khamenei, rising from below $64,000 to $73,770 by Wednesday.

But since then, Bitcoin’s price has fallen over the last four consecutive days.

Trump not worried about oil pricesDespite the boom in oil prices, Trump expects the rapid rise in oil prices to be short-lived: 

“We figured oil prices would go up, which they will. They'll also come down. They'll come down very fast,” Trump told reporters on Saturday.

Trump also shrugged off the idea that the US may need to tap its Strategic Petroleum Reserve, stating:

“We’ve got a lot of oil. Our country has a tremendous amount,” said Trump. “There’s a lot of oil out there. That’ll get healed very quickly.”

Magazine: South Korea gets rich from crypto… North Korea gets weapons

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

In brief Bitcoin is hovering around $66,150, down about 1.7% over the past 24 hours, as volatility spreads across global markets. U.S. stock-index futures tumbled, with Dow futures down more than 800 points while S&P 500 and Nasdaq-100 futures each fell about 1.5%. Oil prices surged above $100 a barrel after strikes on energy infrastructure and disruptions around the Strait of Hormuz raised fears of supply shocks. Bitcoin remained under pressure on Sunday, extending last week's losses as global markets brace for another bout of volatility triggered by surging oil prices and ongoing tensions in the Middle East.

The world’s largest crypto is trading at roughly $66,456, down about 1.7% over the past 24 hours, according to CoinGecko data. 

The token remains up about 1.4% over the past week, though it is down roughly 7.3% over the past month, reflecting choppy trading amid geopolitical tensions and macro uncertainty.

The move came as broader risk markets faced renewed pressure.

Futures tied to the Dow Jones Industrial Average fell more than 800 points, or about 1.7%, while S&P 500 and Nasdaq-100 futures each dropped around 1.5% ahead of the U.S. trading session.

The selloff followed a sharp spike in oil prices tied to the escalating conflict involving Iran.

West Texas Intermediate crude jumped roughly 18% to above $107 a barrel, while Brent crude climbed about 16% to around $108, marking the first time global benchmarks have pushed above the $100 level since 2022.

Growing fears of supply disruptions through the Strait of Hormuz, a narrow shipping corridor that handles roughly one-fifth of global oil shipments, have continued to plague global energy markets.

The spike in crude prices also follows a widening set of attacks on energy infrastructure across the region.

Israeli warplanes struck several fuel storage depots and refinery facilities in Tehran over the weekend, while Iran has launched drone strikes targeting oil tankers and energy sites across the Gulf.

For Bitcoin traders, the key question is whether the shock remains contained to commodities or spreads more broadly across risk assets.

Historically, cryptocurrencies have tended to move in tandem with equities during periods of macro stress.

 A sustained rise in oil prices could amplify inflation concerns and potentially delay interest-rate cuts, tightening financial conditions for speculative assets.

So far, however, Bitcoin has shown relative stability compared with traditional markets.

The token briefly slipped below $66,000 during weekend trading before recovering part of the move, suggesting traders may already have absorbed the initial geopolitical shock.

The geopolitical backdrop also shifted over the weekend after Mojtaba Khamenei, the son of Iran’s late Supreme Leader Ayatollah Ali Khamenei, was named as the country’s new supreme leader, according to Iranian state television.

The elder Khamenei, 86, was killed in an Israeli strike targeting the supreme leader’s offices at the start of the war.

Mojtaba Khamenei, a secretive figure who has never held elected office, will now wield authority over Iran’s military and strategic decision-making, including oversight of the powerful Islamic Revolutionary Guard Corps.

His appointment came on the ninth day of the conflict following deliberations by Iran’s 88-member Assembly of Experts, the clerical body responsible for selecting the country’s supreme leader.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Michael Saylor, the co-founder of Bitcoin (BTC) treasury company Strategy, indicated on Sunday that the firm is buying more BTC, as the price hovers near the $66,000 level. 

“The Second Century Begins,” Saylor said on X, as he shared the Strategy BTC accumulation chart that has become synonymous with impending BTC purchases.

Strategy’s most recent BTC purchase occurred during the last week of February, when the company bought 3,015 BTC for more than $204 million, bringing its total holdings to 720,737 BTC, valued at about $48.1 billion using market prices at the time of publication.

The price of Bitcoin is currently below Strategy’s average purchase cost of about $75,985 per BTC, according to data from SaylorTracker.

Strategy’s Bitcoin purchase history. Source: Michael SaylorThe company continues to accumulate BTC through debt and equity financing, even amid a broad market downturn and a collapse in net asset values (NAVs) for Treasury companies. 

Strategy’s basic NAV is just below 1, according to the company, meaning it is trading at a discount to its BTC treasury.

2026 may be the year of consolidation for crypto treasury companies, but Saylor isn’t buying The digital asset treasury market could consolidate in 2026, as companies with operating businesses that generate cash flow will buy up treasury companies that simply accumulate BTC, according to Wojciech Kaszycki, chief strategy officer of treasury company BTCS.

“If you consolidate with another player, sometimes two plus two equals six or more, you can win faster, because everybody in this market trading below net asset value is struggling,” he told Cointelegraph.

Bitcoin holdings of treasury companies, exchange-traded funds (ETFs), nation-states and decentralized finance wrappers. Source: BitcoinTreasuriesCrypto treasury companies can provide validation services for blockchain networks, mine cryptocurrencies, offer private or public credit instruments, or start any business unrelated to digital assets to generate revenue, he added.

Saylor has dismissed the idea of buying up competitors or distressed BTC treasury companies, citing financial uncertainty as the main reason for avoiding mergers and acquisitions.

“These things tend to stretch out six to nine months or a year,” he said. “An idea that looks good when you start might not still be a good idea six months later,” he added.

Magazine: Mysterious Mr Nakamoto author: Finding Satoshi would hurt Bitcoin

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Strategy's massive bitcoin accumulation is back in focus after Michael Saylor shared a chart highlighting continued corporate buying, reinforcing the firm's position as the largest public-company holder and sparking speculation that another acquisition cycle may be underway.

TLDR: Table of Contents

TLDR:How the Architecture Is Structured Across Three Distinct LayersDigital Credit Bridges Bitcoin and Equity in the StackStrategy’s Digital Equity Completes the Self-Reinforcing System Bitcoin anchors the 3-Layer Architecture as Digital Capital with a fixed supply and no central issuer or counterparty. Stretch functions as Digital Credit, using Bitcoin as collateral to create a superior alternative to traditional fiat-backed credit. Strategy operates as Digital Equity, deploying a reflexive flywheel that compounds Bitcoin Per Share for common equity holders. The 3-Layer Architecture is the first unified capital stack where treasury, credit, and equity are all backed by Bitcoin. The 3-Layer Architecture enabling Strategy to revolutionise finance is drawing attention across global capital markets.

Strategy has built a vertically integrated capital stack that connects Bitcoin, credit, and equity into one coherent system. Each layer feeds the one above it, creating a structure that compounds over time.

This architecture did not exist before Bitcoin made it technically possible. It represents a new category of financial institution that operates entirely outside the traditional monetary framework.

How the Architecture Is Structured Across Three Distinct Layers The 3-Layer Architecture is composed of Digital Capital, Digital Credit, and Digital Equity. Each layer serves a separate function and targets investors with different financial goals.

Bitcoin sits at the bottom as Digital Capital, providing the foundation for everything built above it. Stretch occupies the middle as Digital Credit, while Strategy sits at the top as Digital Equity.

Bitcoin is the only asset with a fixed supply, no issuer, and no central point of failure. No government or central bank can dilute, debase, or seize it.

These properties make it the most reliable foundation for a new financial system. Analyst Chris Millas described it as “the soundest money humanity has ever discovered.”

The architecture is intentionally built from the bottom up. Each layer derives its strength from the layer beneath it. Without sound capital at the base, neither the credit nor the equity layer could function with the same level of integrity.

Digital Credit Bridges Bitcoin and Equity in the Stack Stretch, the Digital Credit layer, acts as the bridge between Bitcoin and Strategy’s equity. Unlike traditional credit, Stretch is collateralised by Bitcoin rather than fiat currency.

This changes the fundamental risk profile of the credit instrument entirely. As Millas noted, “the quality of a credit instrument is only as good as the quality of the collateral backing it.”

Traditional credit rests on fiat — a centralised asset that governments can inflate or seize at any time. Bitcoin-backed credit cannot be manipulated by any central authority.

That structural difference gives Digital Credit a clear advantage over conventional credit products. It also opens a new income category for investors who want Bitcoin exposure without direct price volatility.

Strategy raises capital by issuing these Digital Credit products to investors with varying risk tolerances. That capital flows directly into Bitcoin acquisitions. The credit layer is therefore not passive — it actively powers the equity layer above it.

Strategy’s Digital Equity Completes the Self-Reinforcing System At the top of the 3-Layer Architecture sits Strategy as Digital Equity. It offers a leveraged, reflexive claim on Bitcoin’s appreciation, amplified through the financial engineering of the credit layer below.

As Bitcoin holdings grow, the balance sheet strengthens, attracting more investor capital. That capital then purchases more Bitcoin, and the cycle continues.

Millas described this loop clearly: “More Bitcoin → Stronger Balance Sheet → Stronger Credit Rating → Attract More Capital → More Bitcoin.”

Each rotation through this cycle compounds Strategy’s Bitcoin Per Share for common equity holders. The flywheel accelerates with each pass, not slows down.

Strategy is the first institution to unify treasury, credit, and equity under one Bitcoin-backed capital structure. Millas called this “a new financial primitive” with no direct predecessor in conventional finance.

The 3-Layer Architecture is not a theory — it is already operating and scaling across global capital markets.

Journalist

Posted: March 9, 2026

U.S. congressional debate over a Federal Reserve digital currency has entered a decisive stage as lawmakers push to restrict CBDC development.

A letter from Representative Michael Cloud urges congressional leaders to strengthen restrictions within the 21st Century ROAD to Housing Act.

Initially, the Senate version proposed a temporary CBDC prohibition until December 2030. However, lawmakers argue the language weakens earlier efforts to impose a permanent ban.

This proposal builds on H.R.1919, the Anti-CBDC Surveillance State Act, which previously passed the House with bipartisan backing. At the same time, 14 representatives signed the letter, signaling growing political resistance to a government digital dollar.

Meanwhile, global CBDC experimentation continues to accelerate.

Roughly 137 jurisdictions now explore digital currencies, while 49 operate active pilot programs. Against this, the U.S. policy stance increasingly favors private infrastructure.

XRPL transaction growth signals renewed network activity However, the recent reversal introduces a different dynamic. Daily activity now averages roughly 2.5 million transactions, indicating renewed network engagement across payments and tokenized asset transfers.

Source: CryptoQuant

At the same time, tokenization activity on the ledger is expanding. Represented Asset Value has reached about $1.49 billion, while Distributed  Assets  Value climbed to roughly $453 million.

Meanwhile, transfer activity has accelerated sharply. Over the past 30 days, RWA transfer volumes surged 1,282% to $139.85 million, reflecting growing financial flows across the network.

This growth appears driven by issuers experimenting with commodities, private credit, and alternative assets on XRPL.

Although Ethereum [ETH] still dominates institutional tokenization, rising transaction volumes suggest the XRP Ledger is gradually attracting early-stage institutional experimentation and broader financial participation.

RLUSD emerges as XRPL’s liquidity engine Final Summary Ripple [XRP] transaction growth near 2.5 million daily and expanding tokenized assets suggest rising experimentation with XRPL as infrastructure for payments and tokenized finance. Ripple USD [RLUSD] stablecoin liquidity and the U.S. CBDC policy halt signal a shift where private blockchain networks increasingly shape digital dollar infrastructure.

Did you buy KD securities between August 7, 2024, and February 9, 2026?

Affected Kyndryl Holdings, Inc. Investor Summary

Who: Kyndryl Holdings, Inc. (NYSE: KD) What: Securities fraud class action lawsuit filed Class Period: August 7, 2024, through February 9, 2026 Deadline to Seek Lead Plaintiff Status: April 13, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's cash management practices and internal control over financial reporting. Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to investor , /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities fraud class action lawsuit has been filed against Kyndryl Holdings, Inc. (Kyndryl) (NYSE: KD) on behalf of those who purchased or acquired Kyndryl securities between August 7, 2024, and February 9, 2026, inclusive. The lawsuit is filed in the United States District Court for the Eastern District of New York and is captioned Brander v. Kyndryl Holdings, Inc., et al, Case No. 1:26-cv-00782 (E.D.N.Y.). Investors have until April 13, 2026, to file for lead plaintiff status. 

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Kyndryl Holdings, Inc. securities and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:

(484) 270-1453
[email protected]
https://www.ktmc.com/kd-kyndryl-holdings-inc-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=kd&mktm=PR   

There is no cost or obligation to speak with an attorney.

Learn more about Kyndryl Holdings, Inc. on YouTube:

Kyndryl Holdings, Inc. Securities Class Action Lawsuit (long video) Kyndryl Holdings, Inc. Securities Class Action Lawsuit (short video) KYNDRYL HOLDINGS, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Kyndryl's financial statements issued during the Class Period were materially misstated; (2) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; (3) as a result, Kyndryl would be unable to timely file its quarterly report on Form 10-Q with the SEC for the quarter ended December 31, 2025; and (4) as a result, Defendants' statements about Kyndryl's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Why did Kyndryl's Stock Drop?
On February 9, 2026, Kyndryl surprised investors when it announced that the company's CFO and General Counsel had both departed "effective immediately." Kyndryl also disclosed that, following the company's receipt of voluntary document requests from the SEC, that the company is reviewing its cash management practices related disclosures as well as the efficacy of the company's internal control over financial reporting and certain other matters. Kyndryl further disclosed that it anticipates reporting material weaknesses in the company's internal control over financial reporting. On this news, Kyndryl's stock price fell over 54%, from a close of $23.49 on February 6, 2026, to close at $10.59 on February 9, 2026.

WHAT KD INVESTORS CAN DO NOW:

File to be lead plaintiff by April 13, 2026. Contact KTMC for a free case evaluation. Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR KYNDRYL HOLDINGS, INC. INVESTORS:
Kyndryl investors may, no later than April 13, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Kyndryl investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar.  The firm operates globally with offices in Pennsylvania and California.  KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.  The complaint in this matter was not filed by KTMC.

CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected] 

May be considered attorney advertising in certain jurisdictions.  Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline.

So what: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the REGENXBIO class action, go to https://rosenlegal.com/submit-form/?case_id=53421 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things, REGENXBIO's positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the REGENXBIO class action, go to https://rosenlegal.com/submit-form/?case_id=53421 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Are you looking to add an income-producing component to your current portfolio? There's certainly no shortage of options. If you're looking for simple, productive, and inexpensive choices, an ETF arguably makes the most sense.

But not just any ETF.

While names like the Vanguard Dividend Appreciation ETF (VIG 0.86%) or the Vanguard High Dividend Yield ETF (VYM 0.88%) are respectable options, despite its 19% run-up from its early November low, the Schwab U.S. Dividend Equity ETF (SCHD 0.42%) is still your highest-yielding and most compelling prospect.

The key isn't what it holds, but rather what it doesn't hold.

Image source: Getty Images.

The same, but different One would think any exchange-traded fund with the word "dividend" in the name would be similar. However, that's not the case.

Take the aforementioned Vanguard Dividend Appreciation ETF. It only holds stocks with a long-term track record of annual dividend payment growth, ignoring how much yield shareholders collect from the stocks. This particular Vanguard holds a bunch of technology growth stocks, including Broadcom, Apple, and Microsoft. They pay ever-growing dividends, but none of them actually offer a great deal of dividend income. Its trailing yield is a mere 1.6%.

Regarding the Vanguard High Dividend Yield ETF, it suffers from comparable but different structural limitations. Meant to mirror the FTSE® High Dividend Yield Index, Broadcom is also its biggest holding despite this stock's forward-looking yield of just under 1%. Other major holdings, including JPMorgan Chase, ExxonMobil, and Walmart, are more along the lines of what you'd expect from such an index and fund. Even then, though, these blue-chip stocks' persistent premium pricing means this fund's trailing dividend yield is a modest 2.3%.

The Schwab U.S. Dividend Equity ETF, however, is distinctly different from both of these seemingly good alternatives. Based on the Dow Jones U.S. Dividend 100™ Index, it first and foremost requires strong dividend yields, and then only chooses 100 of these eligible names using important fundamental factors such as free cash flow and return on equity.

Today's Change

(

-0.42

%) $

-0.13

Current Price

$

31.13

The result? Its holdings aren't mostly technology names attached to the artificial intelligence revolution. This ETF's biggest positions include Lockheed Martin, Verizon, and Coca-Cola -- although being an equal-weighted fund, these names won't remain the biggest positions after the end of the current quarter. These are boring non-tech companies, but they fulfill their first and foremost duty of generating good, reliable income. Even with the fund's rally since early November, you'd be plugging into a healthy trailing yield of 3.4%.

Time for a strategic shift as well There's more to the matter than just a dividend yield, of course, like dividend growth. In this vein, the Schwab ETF's quarterly per-share payout has grown a healthy 6.8% annaul pace over the past five years, easily outpacing inflation.

Perhaps the best reason to buy in on SCHD, however, is the less obvious one: It's essentially a value fund in an environment where growth stocks may be on the verge of running out of gas.

Think about it. It's no mere coincidence that this ETF's price has been rising of late while the rest of the growth-led market struggles. Cracks are starting to form for many of the market's hottest tech names, making economically resilient companies like Coca-Cola and Verizon the next must-have stocks.

JPMorgan Chase is an advertising partner of Motley Fool Money. James Brumley has positions in Coca-Cola. The Motley Fool has positions in and recommends Apple, JPMorgan Chase, Microsoft, Vanguard Dividend Appreciation ETF, Vanguard High Dividend Yield ETF, and Walmart. The Motley Fool recommends Broadcom, Lockheed Martin, and Verizon Communications. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - March 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Smart Digital Group Ltd. (NASDAQ: SDM) between May 5, 2025 and September 26, 2025 at 9:34 AM EST, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased SDM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SDM class action, go to https://rosenlegal.com/submit-form/?case_id=50638 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Smart Digital was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) insiders and/or affiliates used and/or intended to use offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Smart Digital's public statements and risk disclosures omitted any mention of realized risk of fraudulent trading or market manipulation used to drive Smart Digital's stock price; (4) as a result, Smart Digital securities were at unique risk of a sustained suspension in trading by either or both of the SEC and NASDAQ; and (5) as a result of the foregoing, defendants' positive statements about Smart Digital's business, operations and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SDM class action, go to https://rosenlegal.com/submit-form/?case_id=50638 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286633

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ardent Health (ARDT) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Ardent Health securities between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, March 08, 2026 (GLOBE NEWSWIRE) --

What’s Happening?

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Ardent Health, Inc. (“Ardent Health” or the “Company”) (NYSE: ARDT) in the United States District Court for the Middle District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Ardent Health securities between July 18, 2024 and November 12, 2025, both dates inclusive (the “Class Period”).Investors have until March 9, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?

According to the complaint, Ardent Health reported higher amounts of accounts receivable during the class period, and delayed recognizing losses on uncollectable accounts. Further, Ardent Health did not maintain professional malpractice liability insurance in amounts "sufficient to cover claims arising out of [its] operations[.]”
Plaintiff alleges that on November 12, 2025, Ardent Health revealed a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after the Company transitioned to a new revenue accounting system and from purported “recently completed hindsight evaluations of historical collection trends.” On this news, the price of Ardent Health stock fell $4.75 per share, or nearly 34%, from $14.05 per share on November 12, 2025, to close at $9.30 per share on November 13, 2025.
What are the Next Steps?

If you purchased or otherwise acquired Ardent Health shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NTLA +2.02%), fits the bill.

Intellia is a mid-cap biotech company specializing in gene editing and developing medicines for diseases for which few exist. The drugmaker has already performed exceptionally well this year, with shares up 47%. Should investors consider purchasing shares of Intellia Therapeutics after this run?

Image source: Getty Images.

Why Intellia's shares are soaring Intellia Therapeutics' two leading pipeline candidates are lonvo-z and nex-z. The former is an investigational treatment for hereditary angioedema, a rare condition that causes painful episodes of swelling across the body, including on the limbs and face. Nex-z targets transthyretin amyloidosis, a genetic disease that results in the malfunctioning of the transthyretin protein and can cause a range of life-threatening cardiovascular issues.

Last year, the U.S. Food and Drug Administration (FDA) put two phase 3 studies for nex-z on clinical hold after a patient died in one of them due to liver failure. Here's the good news: The FDA has now lifted these clinical holds and allowed Intellia Therapeutics to move forward with its clinical studies. Since the stock fell following these negative developments last year, it's not surprising to see it bounce back while the biotech takes a giant step toward putting these issues in the rearview mirror.

Today's Change

(

2.02

%) $

0.27

Current Price

$

13.41

Reasons to be cautious about Intellia Therapeutics Despite the good news, there are good reasons to remain skeptical of Intellia Therapeutics' prospects. First, neither the company nor regulators have revealed whether or not nex-z caused the liver issues that led to the patient's death. Without that bit of information, Intellia Therapeutics could, for all we know, run into similar issues in the near future. True, the company is taking a more careful approach in its late-stage studies for nex-z moving forward.

It will exclude patients with certain liver issues (and several other health problems), for instance, while carefully monitoring signs of liver inflammation. However, the fact that nex-z could still be responsible for the patient's death is a bit worrying. Gene editing medicines already have a hard time ramping up commercial efforts because they are usually costly and complex to administer, making it challenging for third-party payers to adopt them. A lingering safety issue won't make anything easier for the company.

That's before we throw in the usual potential clinical and regulatory roadblocks Intellia Therapeutics could run into that would sink its stock price. True, the company does have things going its way, such as its partnership with biotech giant Regeneron to develop nex-z. Also, there are hundreds of thousands of patients worldwide with transthyretin amyloidosis, and unlike current medicines, nex-z would be a one-and-done treatment for the disease.

These are some reasons Intellia Therapeutics could be a promising biotech. However, given the significant risks, only investors comfortable with heightened volatility should consider the stock.

Tomorrow, AT&T's Chief Financial Officer will participate in a fireside chat at 8:00 a.m. ET to discuss the Company's progress on its multi-year growth strategy Key Takeaways: AT&T's planned new segment reporting, beginning with its first-quarter 2026 results, will provide investors with a better framework for assessing the returns on the Company's growth investments in 5G and fiber.

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

March 08, 2026 18:00 ET  | Source: Dyne Therapeutics, Inc.

- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history -

- Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures -

WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. These data are being presented in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 8-11, 2026, in Orlando, FL, which is available in the Scientific Publications & Presentations section of Dyne’s website along with all of Dyne’s other posters being presented at the conference.

“This week we are presenting additional analyses of 24-month data from the DELIVER trial showing the breadth of potential benefits z-rostudirsen may bring to individuals with exon 51 skip amenable DMD beyond the previously reported unprecedented improvements in muscle function,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. “Cardiopulmonary issues are a key area of concern in DMD, so we are particularly encouraged by new analyses showing improvement in both heart and lung function out to 24 months. We attribute these results to the differentiated capabilities of our FORCE platform to deliver therapeutics to a broad range of muscles, including the heart, trunk and diaphragm, as well as the CNS.”

Dyne announced the results of new analyses of cardiac and pulmonary function amongst all DELIVER participants who were randomized to z-rostudirsen treatment at baseline (any dose1) and for whom cardiac magnetic resonance imaging and/or pulmonary function data were available.

Improvement from baseline in lung function, as measured by Forced Vital Capacity Percent Predicted (FVC%p), was observed through 24 months, as compared to the expected decline estimated in published natural history data2-4.Improvement from baseline was observed through 24 months in circumferential strain, an early signal of cardiac performance, as compared to the expected worsening estimated in published natural history data5,6.Improvement from baseline in left ventricular ejection fraction, a measure of how well the heart is pumping, was observed at 24 months, in contrast with the expected decline estimated in published natural history data5,6.In previously reported safety and tolerability data from 86 total participants enrolled in the DELIVER trial and followed for up to 36 months, z-rostudirsen demonstrated a favorable safety profile7, and most related treatment emergent adverse events (TEAEs) were mild or moderate. The most commonly reported related TEAEs were pyrexia (fever) and headache. No related serious TEAEs were observed in the REC. These data will be presented in a poster titled “Zeleciment rostudirsen led to trends in long-term improvement in clinical outcomes including cardiopulmonary function: Additional data from DELIVER” (poster # 476 LBT).

About the DELIVER Trial
DELIVER is a global, randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial that evaluated the safety, tolerability and efficacy (as measured by both biomarker and functional improvement) of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to exon 51 skipping. The multiple ascending dose (MAD) portion of the study resulted in the selection of a registrational dose and regimen of 20 mg/kg of z-rostudirsen administered every four weeks. The placebo-controlled portion of the registrational expansion cohort (REC) to support a potential regulatory submission for U.S. Accelerated Approval has been completed. The primary endpoint for this cohort was the change from baseline in dystrophin protein levels as measured by Western blot at 6 months. Participants from the MAD and REC portions had the option to enroll in the open-label extension and long-term extension portions of the study. For more information on the DELIVER trial, visit clinicaltrials.gov and euclinicaltrials.eu.

About zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251)
Z-rostudirsen is an investigational therapeutic being evaluated in the Phase 1/2 global DELIVER clinical trial for individuals with DMD who have mutations in the DMD gene that are amenable to exon 51 skipping. Z-rostudirsen consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to an antigen-binding fragment (Fab) that binds to the transferrin receptor 1 (TfR1). It is designed to enable the production of near full-length dystrophin in muscle and the central nervous system (CNS) to provide functional improvement. Z-rostudirsen has received Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA), as well as Orphan Drug designation from the FDA and European Medicines Agency (EMA) and the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of individuals with DMD amenable to exon 51 skipping.

In addition to z-rostudirsen, Dyne is building a DMD franchise and has preclinical programs targeting other exons, including DYNE-253, DYNE-245, DYNE-244 and DYNE-255.

About Duchenne Muscular Dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is a rare X-linked progressive neuromuscular disorder caused by mutations in the DMD gene. These mutations result in a complete or near-complete absence of dystrophin, a protein critical for maintaining muscle structure and function. DMD is the most common form of childhood-onset muscular dystrophy, affecting approximately 12,000 individuals in the U.S. and 16,000 in the EU. Symptoms typically emerge between ages 3 and 5, beginning with muscle weakness in the upper arms, thighs and pelvic region, and progressively impacting the lower limbs, forearms, neck and trunk. In addition to physical decline, individuals may experience cognitive impairment and neuropsychiatric challenges such as intellectual disabilities, learning difficulties and behavioral disorders. Despite existing therapies, there remains a significant unmet need for new treatment options that deliver functional improvement.

About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the clinical potential of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) and its potential cardiopulmonary effects,  and expectations regarding the availability of accelerated approval pathways for z-rostudirsen,  constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies and initial data from clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne's clinical trials and the regulatory approval process; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

The majority of participants at the 24M timepoint initiated treatment at the 0.7–2.8 mg/kg Q4W dose levels. Because most participants accrued substantial time on doses lower than the registrational dose of 20 mg/kg z-rostudirsen Q4W, the observed long-term efficacy potentially does not reflect the effect of continuously maintaining 20 mg/kg Q4W.Meier T, et al. Neuromuscul Disord. 2017;27(4):307–314Mayer OH, et al. Pediatr Pulmonol. 2015;50(5):487–494McDonald CM, et al. Neuromuscul Disord. 2018;28(11):897–909;Batra A, et al. BMC Cardiovasc Disord. 2022;22(1):260;Hagenbuch SC, et al. Am J Cardiol. 2010;105(10):1451–1455;Z-rostudirsen (DYNE-251) safety data as of August 19, 2025. Contacts:

March 08, 2026 18:01 ET  | Source: Dyne Therapeutics, Inc.

- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -

- 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment -

- Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes -

- HARMONIA trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications -

WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the initiation of the Phase 3 HARMONIA trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101), in individuals with myotonic dystrophy type 1 (DM1). The design of the HARMONIA trial is being presented at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on Wednesday, March 11, 2026 at 9:30 a.m. ET. A corresponding poster is also available in the Scientific Publications & Presentations section of Dyne’s website.

“We are proud to be contributing to key advances in myotonic dystrophy clinical research with the initiation of a field-defining Phase 3 study designed to demonstrate the broad potential benefits of z-basivarsen,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. “Building on the ongoing registrational expansion cohort of the Phase 1/2 ACHIEVE trial, which is utilizing myotonia, as measured by video hand opening time, as an early indicator of clinical benefit for potential U.S. Accelerated Approval, HARMONIA is a larger and longer-term study utilizing a clinically meaningful functional measure as the primary endpoint. HARMONIA was designed to reinforce the best-in-class potential of z-basivarsen based on the differentiated capabilities of our FORCE platform to deliver therapeutics to a broad range of muscle systems as well as the CNS.”

HARMONIA is a global, randomized, placebo-controlled, double-blind, confirmatory Phase 3 trial designed to assess the multi-system efficacy, safety, and tolerability of z-basivarsen administered intravenously to individuals with DM1. The trial will enroll approximately 150 participants age 16 and older who will be randomized 1:1 to receive 6.8 mg/kg of z-basivarsen or placebo every eight weeks (Q8W). The first trial sites are activated and open to enrollment.

The primary endpoint is the change from baseline in the five times sit to stand (5xSTS) test at week 49. The 5xSTS test is a reliable and responsive measure that reflects key areas of DM1 impairment, including lower extremity strength, balance and trunk strength, which are critical to performing daily activities. Secondary endpoints include video hand opening time, quantitative muscle testing, the 10-Meter Walk/Run test, the Myotonic Dystrophy Health Index, and additional patient- and clinician-reported outcomes. The trial also includes a broad set of exploratory endpoints designed to assess multiple domains of DM1 central nervous system (CNS) impact. Following the 48-week double-blind placebo-controlled treatment period, patients will be eligible to enroll in a 24-week long-term extension.

Dyne has aligned with the U.S. Food and Drug Administration (FDA) on the HARMONIA Phase 3 trial design and protocol. HARMONIA is intended to serve as a confirmatory trial to support conversion of Accelerated Approval to traditional approval in the U.S. and to support ex-U.S. marketing applications.

About the HARMONIA Trial
HARMONIA is a global, randomized, placebo-controlled, double-blind, confirmatory Phase 3 clinical trial evaluating the efficacy, safety and tolerability of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in people living with myotonic dystrophy type 1 (DM1). The trial will enroll approximately 150 participants age 16 and older who will receive 6.8mg/kg of z-basivarsen or placebo once every eight weeks for 48 weeks, and participants who complete the placebo-controlled period may enter a long-term extension during which all will receive 6.8mg/kg of z-basivarsen every eight weeks for up to 24 additional weeks. The primary endpoint of HARMONIA is the change from baseline in the five times sit to stand (5xSTS) test at week 49. The 5xSTS test is a reliable and responsive measure that reflects key areas of DM1 impairment, including lower extremity strength, balance and trunk strength, which are critical to performing daily activities. Secondary endpoints include video hand opening time, quantitative muscle testing, the 10-Meter Walk/Run test, the Myotonic Dystrophy Health Index, and additional patient- and clinician-reported outcomes. The trial also includes a broad set of exploratory endpoints designed to assess multiple domains of DM1 central nervous system impact.

About zeleciment basivarsen (z-basivarsen, formerly known as DYNE-101)
Z-basivarsen is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE clinical trial for people living with DM1. Z-basivarsen consists of an antisense oligonucleotide (ASO) conjugated to an antigen-binding fragment (Fab) that binds to the transferrin receptor 1 (TfR1) to enable delivery to muscle and the central nervous system. It is designed to deliver functional improvement in individuals living with DM1 by reducing toxic nuclear DMPK RNA to release splicing proteins and allow normal mRNA processing. Z-basivarsen has been granted Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA), as well as Orphan Drug designation from the European Medicines Agency (EMA) and the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of DM1.

About Myotonic Dystrophy Type 1 (DM1)
Myotonic dystrophy type 1 (DM1) is a rare, progressive, genetic neuromuscular disease with high morbidity and early mortality. DM1 affects ~40,000 people in the U.S. and ~55,000 people in the EU. The severity of symptoms and rate of progression varies. Symptoms can begin at any point in an affected person’s life, depending on the DM1 subtype. Adult-onset DM1 symptoms typically appear between 20 to 40 years of age. DM1 is caused by mutations in the DMPK gene, leading to a widespread disruption of RNA splicing, known as spliceopathy, which drives the multi-system manifestations of the disease. People experience a broad spectrum of symptoms, including: muscle weakness throughout the body, myotonia or difficulty relaxing muscles, excessive daytime sleepiness, fatigue, dysregulated sleep, cognitive impairments, cardiac arrhythmias, respiratory issues and gastrointestinal dysfunction. Although the genetic cause of DM1 is well understood, there are currently no approved disease-modifying treatments for DM1.

About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the clinical potential of zeleciment basivarsen (z-basivarsen, also known as DYNE-101), the potential of video hand opening time to serve as an intermediate clinical endpoint for U.S. accelerated approval, and the capability of Dyne’s FORCE platform to deliver therapeutics to a broad range of muscle systems as well as the central nervous system, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to enroll patients in clinical trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne's clinical trials and the regulatory approval process; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contacts:

New York, New York--(Newsfile Corp. - March 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Vistagen class action, go to https://rosenlegal.com/submit-form/?case_id=50827 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning Vistagen's plan to develop and commercialize its drug fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD). Defendants' statements included, among other things, Vistagen's positive assertions of fasedienol's future trial success based on the prior positive results associated with the PALISADE-2 clinical trial, in addition to notable enhancements and operational changes made to the execution of the PALISADE-3 clinical trial supported a strong likelihood of Phase 3 success and positioned it as a confirmatory study.

According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Vistagen class action, go to https://rosenlegal.com/submit-form/?case_id=50827 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286631

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Darius Baruo Mar 08, 2026 19:47

FLOKI shows oversold conditions at $0.00002774 with RSI at 39.72. Technical analysis suggests potential recovery to $0.000048-$0.000050 range within weeks as meme coin finds support.

FLOKI Price Prediction Summary • Short-term target (1 week): $0.000032 • Medium-term forecast (1 month): $0.000048-$0.000050 range
• Bullish breakout level: $0.000055 • Critical support: $0.000025

What Crypto Analysts Are Saying About Floki While specific analyst predictions from major KOLs are limited in the current market cycle, recent technical analysis from cryptocurrency researchers provides insight into FLOKI's potential trajectory.

Felix Pinkston noted in early March 2026 that "FLOKI trades at $0.00002779 with RSI at 37.14 suggesting oversold bounce potential. Technical analysis points to $0.000048-$0.000050 recovery target within weeks." This aligns with current technical conditions showing similar oversold readings.

Caroline Bishop highlighted in late February that "FLOKI shows oversold conditions at $0.00002676 with RSI at 35.10," indicating potential for a technical rebound. With current RSI readings at 39.72, the oversold bounce thesis remains relevant for this FLOKI price prediction.

According to on-chain data, FLOKI's trading volume has maintained stability at $1.96 million over the past 24 hours, suggesting sustained interest despite recent price consolidation.

FLOKI Technical Analysis Breakdown The current FLOKI price prediction is heavily influenced by key technical indicators showing mixed but improving signals. At the current price of $0.00002774, FLOKI has shown a modest 0.33% gain in the past 24 hours, indicating potential stabilization after recent volatility.

The RSI reading of 39.72 places FLOKI in neutral territory with a slight oversold bias, historically a favorable condition for meme coin recoveries. This supports the bullish elements of our Floki forecast, as RSI levels below 40 often precede upward price movements in cryptocurrency markets.

The MACD histogram shows bearish momentum at 0.0000, though this flat reading suggests the selling pressure may be exhausting. Stochastic indicators with %K at 23.05 and %D at 18.44 confirm oversold conditions, supporting the recovery thesis in this FLOKI price prediction.

Bollinger Band positioning at 0.24 indicates FLOKI is trading closer to the lower band, typically signaling oversold conditions and potential for mean reversion toward the middle band.

Floki Price Targets: Bull vs Bear Case Bullish Scenario The optimistic Floki forecast targets the $0.000048-$0.000050 range based on technical resistance levels and historical recovery patterns. This represents an 80% upside from current levels and aligns with analyst projections from early March.

Key bullish catalysts include RSI recovery above 50, MACD histogram turning positive, and a break above the 20-day moving average. Volume expansion above the current $1.96 million daily average would provide additional confirmation for this FLOKI price prediction.

A breakout above $0.000055 could target the next resistance zone around $0.000065, representing the more aggressive bull case scenario.

Bearish Scenario The downside risk in this Floki forecast centers around the critical support level at $0.000025. A break below this level could trigger additional selling pressure, potentially targeting $0.000020 or lower.

Risk factors include continued MACD bearish divergence, failure to reclaim the middle Bollinger Band, and broader cryptocurrency market weakness. The meme coin sector's volatility adds additional downside risk to any FLOKI price prediction.

Should You Buy FLOKI? Entry Strategy Based on current technical analysis, potential entry points for FLOKI include the current level around $0.000027-$0.000028, with a more conservative entry on any dip toward $0.000025 support.

A stop-loss below $0.000022 would limit downside risk while allowing for normal price fluctuations. Given the volatile nature of meme coins, position sizing should remain conservative, with FLOKI representing no more than 1-2% of a diversified cryptocurrency portfolio.

Risk management is crucial given that this FLOKI price prediction operates in a highly speculative market segment prone to sudden sentiment shifts.

Conclusion This FLOKI price prediction suggests a cautiously optimistic outlook with potential for recovery to the $0.000048-$0.000050 range over the coming weeks. The combination of oversold technical conditions and analyst projections supports this Floki forecast, though traders should remain aware of the inherent volatility in meme coin markets.

The technical setup appears favorable for a bounce, but confirmation through increased volume and RSI improvement above 50 would strengthen the bullish case. As with all cryptocurrency price predictions, market conditions can change rapidly, and this analysis should not be considered financial advice.

Disclaimer: Cryptocurrency investments carry significant risk. This FLOKI price prediction is for informational purposes only and should not be construed as financial advice. Always conduct your own research and consider your risk tolerance before investing.

Image source: Shutterstock

floki price analysis floki price prediction

Luisa Crawford Mar 08, 2026 19:59

INJ Price Prediction Summary • Short-term target (1 week): $3.22 • Medium-term forecast (1 month): $3.44-$3.60 range • Bullish breakout level: $2.93 • Critical support: $2.74 What Crypto Anal...

INJ Price Prediction Summary • Short-term target (1 week): $3.22 • Medium-term forecast (1 month): $3.44-$3.60 range
• Bullish breakout level: $2.93 • Critical support: $2.74

What Crypto Analysts Are Saying About Injective Recent analyst coverage from early March provides insight into Injective's potential trajectory. Caroline Bishop projected on March 3rd that "Injective (INJ) trades at $3.03 with neutral RSI and technical consolidation. Analysts project $3.44-$3.60 near-term recovery as INJ approaches key resistance levels."

Rongchai Wang offered a more optimistic outlook on March 4th, stating "INJ trades at $3.10 with neutral RSI at 43.49. Analysts project $3.60-$6.50 recovery potential as Injective approaches key resistance breakout at $3.22."

Tony Kim focused on short-term bounce potential, noting "INJ shows oversold bounce potential from $3.06 support, targeting $3.54 resistance with neutral RSI at 40.89 suggesting possible short-term recovery ahead."

However, these predictions were made when INJ was trading above $3.00, and the token has since declined to $2.84, suggesting market conditions have deteriorated since these forecasts were issued.

INJ Technical Analysis Breakdown The current technical picture for Injective presents mixed signals with bearish undertones. Trading at $2.84, INJ sits well below all major moving averages, with the 7-day SMA at $2.98 and 20-day SMA at $3.15 acting as immediate resistance barriers.

The RSI reading of 37.44 indicates neutral territory with oversold conditions approaching, which could signal a potential bounce. However, the MACD histogram at 0.0000 shows bearish momentum remains intact, while the extremely low Stochastic readings (%K at 6.02, %D at 4.82) suggest the token is in oversold territory.

Bollinger Band analysis reveals INJ trading near the lower band support at $2.70, with a %B position of 0.1524 indicating the price is much closer to the lower band than the upper band at $3.61. This positioning often precedes either a bounce or a breakdown.

The daily ATR of $0.25 indicates moderate volatility, while the 24-hour trading range of $2.78-$2.88 shows relatively tight price action within a $0.10 range.

Injective Price Targets: Bull vs Bear Case Bullish Scenario For an INJ price prediction to turn bullish, the token needs to reclaim the $2.93 strong resistance level, which would confirm a break above the recent trading range. Success here could target the immediate resistance at $3.15 (20-day SMA), followed by the analyst-projected $3.22 breakout level mentioned by Wang.

A sustained move above $3.22 could validate the more optimistic Injective forecast targeting $3.44-$3.60, aligning with Bishop's projections. The ultimate bullish target of $6.50 would require significant fundamental catalysts and broader market support.

Bearish Scenario The bearish case for this INJ price prediction centers on the failure to hold current support levels. A break below the immediate support at $2.79 could accelerate selling toward the strong support at $2.74.

Given the positioning near the lower Bollinger Band at $2.70, a breakdown could see INJ testing this technical floor. Further deterioration could target the psychologically important $2.50 level, representing a significant decline from current analyst price targets.

Should You Buy INJ? Entry Strategy Based on current technicals, aggressive buyers might consider accumulating near the $2.74-$2.79 support zone, with a tight stop-loss below $2.70 to limit downside risk. Conservative investors should wait for a clear break and hold above $2.93 before considering entry.

For those following the analyst Injective forecast, scaling into positions between $2.70-$2.85 could provide favorable risk-reward ratios if the $3.44-$3.60 targets materialize. However, position sizing should reflect the high-risk nature of cryptocurrency investments.

A disciplined approach would involve taking partial profits at $3.15 and $3.44 levels while maintaining core positions for the higher targets if momentum continues.

Conclusion This INJ price prediction suggests cautious optimism despite current technical weakness. While recent analyst forecasts project recovery to $3.44-$6.50, the deterioration from $3.10 to $2.84 indicates these targets may take longer to achieve than initially anticipated.

The oversold technical conditions provide potential for a near-term bounce, but sustainable recovery requires clearing multiple resistance levels. Investors should approach with appropriate risk management and recognize that cryptocurrency price predictions carry inherent uncertainty.

This analysis is for informational purposes only and should not be considered financial advice. Cryptocurrency investments carry significant risk of loss.

Image source: Shutterstock

inj price analysis inj price prediction

Ted Hisokawa Mar 08, 2026 20:16

PEPE shows oversold conditions with RSI at 33.36 and trading near lower Bollinger Band support. Technical indicators suggest potential bounce from current levels despite recent 2.45% decline.

PEPE Price Prediction Summary • Short-term target (1 week): Limited upside potential due to bearish momentum • Medium-term forecast (1 month): $0.0000070-$0.0000072 range per recent analysis • Bullish breakout level: Above current resistance zones • Critical support: Current lower Bollinger Band levels

What Crypto Analysts Are Saying About Pepe While specific analyst predictions from key opinion leaders are limited in recent trading sessions, available forecasts provide some insight into PEPE's potential trajectory. According to MEXC News analysis from January 30, 2026, "PEPE price prediction shows potential 30-35% rally to $0.0000070-$0.0000072 range by month-end, despite current bearish momentum and oversold technical conditions."

More recently, Blockchain.News noted on March 7, 2026, that "PEPE shows oversold signals with RSI at 36.23 and trading near lower Bollinger Band. Technical analysis suggests potential bounce from current support levels."

On-chain data and technical metrics continue to play a crucial role in PEPE price prediction models, with platforms like CryptoQuant and Glassnode providing valuable insights into meme coin market dynamics.

PEPE Technical Analysis Breakdown Current technical indicators paint a mixed picture for Pepe, with several oversold signals emerging alongside bearish momentum patterns.

The Relative Strength Index (RSI) sits at 33.36, placing PEPE in neutral territory but approaching oversold conditions. This RSI reading suggests the recent selling pressure may be approaching exhaustion, potentially setting up for a technical bounce.

PEPE's MACD histogram shows 0.0000, indicating bearish momentum continues to dominate price action. The convergence of MACD lines suggests indecision in the market, with neither bulls nor bears establishing clear control.

Bollinger Band analysis reveals PEPE trading at a %B position of 0.0776, meaning the token is positioned very close to the lower Bollinger Band. This positioning often indicates oversold conditions and potential support levels.

The Stochastic oscillator readings show %K at 3.79 and %D at 3.03, both in deeply oversold territory. These extreme readings historically precede short-term bounces in volatile assets like meme coins.

Trading volume on Binance spot markets reached $20,295,923 in the past 24 hours, indicating maintained interest despite the 2.45% price decline.

Pepe Price Targets: Bull vs Bear Case Bullish Scenario The bullish case for PEPE hinges on the current oversold technical conditions translating into a meaningful recovery. Based on the MEXC analysis, a successful bounce could target the $0.0000070-$0.0000072 range, representing a potential 30-35% upside from oversold levels.

Key technical confirmation would come from RSI breaking above 40, indicating momentum shift from oversold conditions. Additionally, MACD histogram turning positive would signal strengthening bullish momentum.

The Pepe forecast becomes more optimistic if trading volume increases during any recovery attempt, suggesting genuine buying interest rather than short-covering.

Bearish Scenario The bearish scenario remains viable given the current MACD bearish momentum and recent price decline. Failure to hold lower Bollinger Band support could trigger additional selling pressure.

Risk factors include broader meme coin market weakness and continued crypto market uncertainty. A break below current support levels could target deeper oversold readings and extended consolidation periods.

The negative MACD histogram suggests sellers may still have control, particularly if broader market conditions deteriorate.

Should You Buy PEPE? Entry Strategy Given the current technical setup, potential entry strategies should focus on oversold bounce plays while maintaining strict risk management.

Conservative entry points would wait for RSI to confirm above 40 and initial MACD histogram improvement. This approach reduces the risk of catching a falling knife while still capitalizing on oversold conditions.

Aggressive traders might consider current levels given the extreme oversold readings, but should implement tight stop-losses below recent support zones to limit downside exposure.

Position sizing should reflect PEPE's high volatility profile, with most analysts recommending no more than 1-3% portfolio allocation to speculative meme coin positions.

Conclusion The PEPE price prediction outlook remains cautiously optimistic based on current oversold technical conditions, despite ongoing bearish momentum. While the immediate trend shows weakness with the 2.45% decline, multiple oversold indicators suggest potential for a technical bounce.

The medium-term Pepe forecast aligns with analyst projections targeting the $0.0000070-$0.0000072 range, though this depends heavily on broader market conditions and sustained buying interest. Traders should monitor RSI recovery above 40 and MACD histogram improvement as key confirmation signals.

Disclaimer: Cryptocurrency price predictions are inherently speculative and carry significant risk. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

pepe price analysis pepe price prediction

BNB price is moving near $614 after a US federal court dismissed all anti-terrorism claims against Binance. The ruling removes a major legal overhang, but the price remains under technical pressure.

A federal judge in the Southern District of New York dismissed all claims filed under the Anti-Terrorism Act. The lawsuit, as we reported, involved 535 plaintiffs who cited 64 attacks between 2017 and 2024. The court found that the plaintiffs failed to prove that Binance assisted or conspired with terrorist groups.

Court Dismisses All ATA Claims Against BinanceThe 62-page decision rejected every central allegation against Binance and founder Changpeng Zhao. The court stated that the plaintiffs failed to show direct participation or intent. It ruled that exchange access alone did not establish liability.

Eleanor Hughes, Binance General Counsel, said the dismissal represents a full rejection of the claims. She stated that the court rejected what she called a false narrative. The court allowed plaintiffs 60 days to file an amended complaint.

Binance stated that it remains confident no amended filing can fix the deficiencies identified. The company said it will continue to defend itself against litigation. It also confirmed ongoing engagement with regulators worldwide.

The lawsuit followed earlier regulatory scrutiny in the United States. In 2023, Binance agreed to a $4.3 billion settlement over sanctions and AML violations. That settlement remains separate from the ATA case.

Binance Responds to Senate Inquiry and Compliance QuestionsBinance also responded to an inquiry from Senator Richard Blumenthal. The company disputed media claims and called certain allegations unsupported. It stated that users located in Iran are prohibited from using the platform.

Binance said it found no direct transactions with Iran-based entities. It added that it first learned of named entities through law enforcement inquiries. The exchange said it investigated and off boarded the accounts involved.

Changpeng Zhao posted that false news is temporary and truth takes time. Teresa Goody Guillén also confirmed that the court dismissed every claim. She stated that the plaintiffs failed to tie Binance or Zhao to financing attacks.

BNB Price Structure Remains Bearish Below Key ResistanceDespite the legal win, BNB remains in a short-term downtrend on the daily chart. Price previously broke down from the $880 to $900 region. The move erased several support levels in a short period.

BNB trades below the 20-day simple moving average near $621. The upper Bollinger Band sits near $653 and acts as resistance. The lower Bollinger Band near $588 offers short-term support.

Source: TradingView

The RSI reads around 41 and remains below the neutral 50 level. Selling pressure has slowed, but bullish momentum has not returned. Traders are now watching the $650 to $700 zone for a recovery attempt.

If BNB fails to hold $588, the price may retest $560. A deeper move toward $520 to $500 remains possible if weakness continues. However, a break above $650 could open a path toward $720 to $750.

Bitcoin Price Prediction: Can BTC Recover After the Drop to $66K?Bitcoin is currently trading near $66,000 after experiencing a sharp correction from its recent highs. After reaching levels above $120,000 earlier in the cycle, BTC has now lost almost half of its value during the latest market reset.

While some investors fear the bull market may be ending, historical patterns suggest these corrections are often a normal part of the Bitcoin cycle.

The key question now is whether Bitcoin is preparing for a recovery — or if another leg down could still occur.

Bitcoin Is Consolidating After a Major CorrectionBitcoin’s recent drop follows a familiar pattern seen in previous cycles.

In past bull markets, BTC often experiences 40–60% corrections before continuing upward.

By TradingView - BTCUSD_2026-03-08 (All)Examples include:

2017 cycle: BTC dropped from $20K to $10K before continuing the trend.2021 cycle: BTC fell from $64K to $30K before the next rally.2026 cycle: BTC dropped from around $127K to nearly $62K.This pattern shows that sharp corrections do not necessarily signal the end of a bull market.

Instead, they often represent a cooling-off phase after excessive leverage and speculation.

Key Support Levels for BitcoinFrom a technical perspective, several levels are now important for Bitcoin traders.

Major support zones:

$62,000 – $64,000 (cycle low area)$58,000 – $60,000 (strong historical demand zone)If Bitcoin remains above these levels, the broader bullish structure could remain intact.

Key Resistance Levels to WatchFor Bitcoin to regain bullish momentum, it would need to reclaim several resistance zones:

$70,000 psychological resistance$75,000 – $80,000 previous consolidation range$100,000+ long-term breakout targetBy TradingView - BTCUSD_2026-03-08 (5Y)A break above $70K could signal renewed bullish momentum across the crypto market.

Macro Events Are Adding VolatilityBitcoin’s recent volatility is also occurring alongside major global developments.

Markets are currently reacting to:

Rising oil pricesEscalating geopolitical tensions in the Middle EastIncreasing uncertainty across global financial marketsDuring these periods, investors often temporarily reduce exposure to risk assets such as cryptocurrencies.

However, some analysts argue that prolonged macro instability could eventually strengthen Bitcoin’s narrative as a hedge against global uncertainty.

Bitcoin Price PredictionBased on the current structure, three main scenarios could unfold.

Bullish scenario

BTC holds above $64K supportBreakout above $70KPossible rally toward $80K–$90KNeutral scenario

Bitcoin consolidates between $60K and $70K for several weeksBearish scenario

Breakdown below $60KPossible retest of $50K–$55KFor now, Bitcoin appears to be entering a consolidation phase, where the market resets before the next major move.